Yeh Yung-Ping 4
4 · Vyant Bio, Inc. · Filed Apr 1, 2021
Insider Transaction Report
Form 4
Vyant Bio, Inc.VYNT
Yeh Yung-Ping
DirectorChief Innovation Officer
Transactions
- Other
Stock option (right to buy)
2021-03-30+51,825→ 51,825 totalExercise: $1.56Exp: 2030-05-22→ Common stock (51,825 underlying) - Award
Stock option (right to buy)
2021-03-30+150,000→ 150,000 totalExercise: $4.61Exp: 2031-03-30→ Common stock (150,000 underlying) - Other
Common Stock, $0.0001 par value
2021-03-30+1,328,602→ 1,328,602 total
Footnotes (3)
- [F1]Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.
- [F2]Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 51,825 options vest upon the achievement of certain milestones.
- [F3]The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. Subject to continued employment, the option vests as to 25% of the shares on March 30, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on April 30, 2022.